ChartTrends: Rheumatoid Arthritis 2015 (US) provides insight into the management and treatment of RA patients by rheumatologists based on actual patient-level data. 224 rheumatologists provided data on 999 biologic/Xeljanz-treated RA patients and were surveyed to examine what they self-report about disease management along with chart audit data for RA patients. Through an in-depth review of specific patient charts, details such as product dosing and frequency, prior medications/switching analysis, concomitant medications, and patient demographic variables help identify treatment approaches for RA.

Questions Answered in This Report:

  • Established TNF-α inhibitors are still leading the biologic patient share among audited RA patients. How much market share has more-recently launched RA products gained?

  • Products that rheumatologists deem to be efficacious are important considerations when initiating RA treatment. How can newcomers compete with established products in the RA disease market?

  • There are several new products in the RA pipeline that have mechanisms of action that differ from those of the well-established TNF-inhibiting biologics. How will forthcoming products for RA impact current brands?


Markets covered: United States.

Primary research: 224 U.S. rheumatologists currently in clinical practice who treat a minimum of 100 RA patients (at least 50 of those patients need to be on biological agents), who have practiced between 2 and 30 years, and who spend more than 75% of their time in clinical practice. Upon completion of the Physician Profile Survey, respondents were directed to complete patient audits for 3-6 of their RA patients. Physicians were instructed to pick charts at random for patients they have personally seen within the past six months. Patients must be between the ages of 18 and 90 and be currently treated with an FDA-approved RA biologic or Xeljanz.

Methodology: 15-minute online survey for the physician profile with 3-6 patient charts per physician for the patient audit. Patient chart review takes 15 minutes each to complete.

Emerging therapies: Phase III: baricitinib, sarilumab, sirukumab, secukinumab.

Author(s): Bingnan Kang, Ph.D

Related Reports

Rheumatoid Arthritis | Landscape & Forecast | Disease Landscape & Forecast

The increasingly crowded RA market boasts many different targeted agents representing several distinct drug classes, including blockbuster

View Details

Rheumatoid Arthritis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, together with conventional treatments...

View Details

Rheumatoid Arthritis | Geographic Focus - China | Rheumatoid Arthritis - China In-Depth - China

MARKET OUTLOOK Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that prima...

View Details

Rheumatoid Arthritis | Emerging Therapies | Olumiant (Baricitinib) Launch Tracking Wave 3

Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak inhibito...

View Details